Hainy, Caitlin M.

Objective: To evaluate the effectiveness of a standardized hazardous medication surveillance program and identify occupational factors associated with adverse health outcomes among healthcare workers (HCWs). Methods: We analyzed data from 2,625 HCWs enrolled in a multi-site surveillance program (2020–2022). Participants completed a standardized questionnaire and underwent complete blood count testing. Exposure was categorized by weekly time handling hazardous medications. Associations were evaluated using univariate and multivariable analyses. Results: Higher exposure (>8 hours/week) was associated with increased symptom reporting, hazardous medication spills, and adverse reproductive outcomes. Female sex, older age, and spill exposure independently predicted symptom reporting and reproductive outcomes. No significant association was observed between exposure intensity and abnormal blood counts. Conclusion: Questionnaire-based surveillance effectively identified exposure-related health risks, whereas routine complete blood count testing showed limited utility.

The COVID-19 pandemic disrupted the workforce, resulting in a shift to a largely remote working population. As a result of this shift, Employee Occupational Health Services (EOHS) was required to develop a solution to evaluate new employees and provide occupational medical clearance without the physical presence of the candidate. An online candidate portal was created where individuals could complete evaluation paperwork and screenings asynchronously. The evaluation forms and screenings were then reviewed by occupational health nursing staff, and testing was conducted in the candidate’s home location. The virtual evaluation solution expedited the assessment process, added convenience for candidates and reduced the amount of time needed from EOHS staff. It is imperative that EOHS departments adjust to the changing workforce by offering virtual evaluation solutions that provide candidates with a seamless and efficient solution to complete required paperwork, testing and immunisations.

Abstract In a large cohort of United States healthcare personnel without prior coronavirus disease 2019 (COVID-19) infection, 94 382 doses of messenger RNA (mRNA) COVID-19 vaccine were administered to 49 220 individuals. The adjusted vaccine effectiveness following 2 doses of each of the 2 available brands of mRNA vaccine exceeded 96%.